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Dominant mutations in the gene encoding the ubiquitously-expressed splicing factor PRPF31 cause retinitis
pigmentosa, a form of hereditary retinal degeneration, with reduced penetrance. We and others have pre-
viously shown that penetrance is tightly correlated with PRPF31 expression, as lymphoblastoid cell lines
(LCLs) from affected patients produce less abundant PRPF31 transcripts than LCLs from their unaffected
relatives carrying the same mutation. We have investigated the genetic elements determining the variable
expression of PRPF31, and therefore possibly influencing the penetrance of its mutations, by quantifying
PRPF31 mRNA levels in LCLs derived from 15 CEPH families (200 individuals), representative of the general
population. We found that PRPF31 transcript abundance was a highly variable and highly heritable character.
Moreover, by linkage analysis we showed that PRPF31 expression was significantly associated with at least
one expression quantitative trait locus (eQTL), spanning a 8.2-Mb region on chromosome 14q21–23. We also
investigated a previously mapped penetrance factor located near PRPF31 itself in LCLs from individuals
belonging to selected families segregating PRPF31mutations that displayed reduced penetrance. Our results
indicate that, despite its constant association with the non-mutant allele, this factor was able to modulate the
expression of both PRPF31 alleles. Furthermore, we showed that LCLs from affected patients have less
PRPF31 RNA than those of asymptomatic patients, even at the pre-splicing stage. Altogether, these data
demonstrate that PRPF31 mRNA expression and consequently the penetrance of PRPF31 mutations is
managed by diffusible compounds encoded by at least two modifiers, acting in a co-regulatory system on
both PRPF31 alleles during transcription.
INTRODUCTION
Retinitis pigmentosa (RP) is a heterogeneous group of neuro-
degenerative diseases affecting the retina by causing the
progressive death of photoreceptor cells. RP occurs alone or
as a part of more complex syndromes. Evolution of RP is an
exponential progression of symptoms, usually night blindness,
loss of mid-peripheral visual field, loss of peripheral vision by
visual field constriction, and in many cases complete or near-
complete blindness, as a final stage. Physiologically, first the
outer segment of photoreceptors and then the outer nuclear
layer of the retina disappear, followed by the degeneration of
the inner and ganglion cell layers (1). Clinically, analysis of
retinal fundi typically exhibits bone spicule-like pigmentary
deposits, due to retinal pigmented epithelium migration in the
retina (2), and electroretinograms show reduced or absent
amplitudes and delayed signals (3). RP is genetically highly
heterogeneous and mostly a monogenic disorder. It is trans-
mitted as a Mendelian autosomal dominant, autosomal reces-
sive or X-linked character, and in small proportions also as a
digenic and a non-Mendelian trait (4). So far, mutations in
almost 80 genes have been found to cause RP (http://www.
sph.uth.tmc.edu/Retnet/).
Some of the genes causing RP encode proteins which are
exclusively present or have a predominant role in the retina.
Other RP genes are ubiquitously expressed and encode
proteins that do not have any known retina-specific function.
The mechanisms by which mutations in these genes, that are
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sometimes essential and highly conserved, produce a retina-
restricted phenotype remain unknown. PRPF31, a protein
component of the spliceosome complex, is ubiquitously
expressed and essential for cell survival (5). Distinct heterozy-
gous PRPF31 mutations were shown, however, to cause
autosomal dominant RP (ADRP) with no associated syndro-
mic symptoms (6–26), and were all found to map to the
RP11 locus on chromosome 19q13.4 (13,27), which accounts
for 5% of ADRP cases (1).
A particular clinical feature of RP11-linked RP is the pre-
sence, in some pedigrees, of asymptomatic carriers of patho-
genic mutations showing no impaired vision and normal to
slightly reduced electroretinographic recordings, suggesting
incomplete penetrance of symptoms. These individuals are
rarely identified with a routine clinical examination, since
they never develop any significant clinical manifestations,
even at old ages, but can generate offspring that are affected
with RP (6–12,14,18–20,22–26). Linkage analyses per-
formed with markers located around the RP11 locus have
demonstrated that the penetrance of mutations is presumably
determined by particular alleles, termed isoalleles, that are
inherited from the parent who does not carry the mutation
(i.e. they are in trans with respect to the mutation), and are
located close to or within the RP11 locus itself (Fig. 1)
(12,13). These isoalleles (from now on called ‘RP11-associated
isoalleles’) are assumed to be present in the general population
and would not produce any clinical phenotype by themselves,
but may determine or modulate the pathogenic effects of
PRPF31 mutations, when present. However, RP11-associated
isoalleles alone cannot explain penetrance in some families
segregating PRPF31 mutations, indicating that other modifiers
could be involved (12).
Since retinal biopsies are impossible and PRPF31 is ubi-
quitously expressed, lymphoblastoid cell lines (LCLs) from
carriers of mutations have been used by us and others as an
excellent biological proxy for photoreceptors in PRPF31 mol-
ecular studies (21,28,29). Such investigations have allowed to
determine that haploinsufficiency is the likely cause of the
disease, as the large majority of PRPF31 mutations result in
functionally null alleles. Specifically, LCLs from unaffected
controls were shown to express substantially more PRPF31
mRNA than LCLs from carriers of PRPF31 mutations, as
mutant PRPF31 mRNA alleles in both affected and asympto-
matic patients are either degraded by the nonsense-mediated
mRNA decay (29) or absent due to the deletion of one copy
of the gene (19,22). Very interestingly, LCLs from asympto-
matic patients express higher levels of the non-mutant
PRPF31 mRNA allele than LCLs from affected patients
(21,26,28). This indicates that, regardless of the specific
mutation, higher expression of functional PRPF31 mRNA
may protect asymptomatic carriers from the disease and
explain incomplete penetrance. A similar mechanism has
been identified in at least two other dominant diseases with
incomplete penetrance. Specifically, penetrance of mutations
in the a-subunit of the spectrin gene (SPTA1) and in the ferro-
chelatase gene (FECH), leading to hereditary elliptocytosis
and erythropoietic protoporphyria, respectively, is also
determined by variations in the expression of the wild-type
allele, modulated by a cis-acting polymorphism (30,31). Con-
sequently, it can be hypothesized that genetic modifiers can
determine the clinical status of carriers of PRPF31 mutations,
by modulating the expression of non-mutant PRPF31 alleles.
The aim of the present study is to identify the genetic
elements that control the expression of PRPF31 and therefore
to gain insights into the heritable factors involved in determin-
ing the penetrance of its mutations.
RESULTS
PRPF31 expression and its heritability
Variable PRPF31 expression was proven to be directly corre-
lated with penetrance of its mutations (21,26,28). We first
investigated whether differential amounts of PRPF31 mRNA
could be a consequence of polymorphic copy number
variations (CNVs), found to be important factors in human
phenotypic variability (32). A scan of the Database of
Genomic Variants (33) for possible CNV sequences spanning
the PRPF31 region revealed the absence of polymorphic
variations in copy number. Direct analysis by genomic DNA
real-time PCR of all PRPF31 exons in one affected and two
asymptomatic patients from the same family, as well as in
three control individuals, also showed that there were neither
deletions nor duplications, in any of the samples (Supplemen-
tary Material, Fig. S1).
We then wanted to refine the mapping of RP11-associated
isoalleles and, possibly, detect new modulators of PRPF31
expression. For this purpose, we measured the expression of
PRPF31 mRNA in 200 LCLs from 15 CEPH families, by
highly sensitive real-time PCR set-ups. Thirteen of these pedi-
grees were three-generation families (grand parents, parents
and children), while the remainder were composed of
parents and children only, with an overall average of 9.5
sibs per family. For each individual, we normalized the
expression of PRPF31 using GAPDH transcripts as endogen-
ous controls, described as reliable standards for correlating
PRPF31 expression and clinical status of LCL donors, accord-
ing to our results (not shown) and data from other groups (28).
The relative expression was calculated with respect to the
median PRPF31 expressor, arbitrarily set to an expression
value of 1.0. The distribution of the phenotypes showed
that the amount of PRPF31 transcripts were far from being
Figure 1. RP11-associated isoalleles and penetrance of PRPF31 mutations,
according to the model by McGee et al. (12). A hypothetical family segregat-
ing the PRPF31mutation M is depicted. RP11-associated isoalleles (A), inher-
ited from the parent that does not carry the mutation and polymorphic in the
general population, protect an asymptomatic patient (symbol with a dot) from
the disease. Conversely, when this isoallele is not present (a), PRPF31
mutations cause RP.
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constant in the general population, as they varied from 0.53 to
2.48 arbitrary units (a.u.), representing a ~5-fold change
between the lowest and the highest expressor (Fig. 2).
To confirm the robustness of these data, PRPF31 expression
was also measured in seven LCLs from clinically affected
patients carrying one of the following PRPF31 mutations:
c.177þ1delG, c.323-2A.G, c.877_910del, c.319C.G and
c.856-2A.G, that were previously found to express patho-
logically low levels of PRPF31 transcripts (21). In these
cells, normalized PRPF31 expression varied from 0.29 to
0.50 a.u. (Fig. 2) and was, as expected, lower than in the
general population (P ¼ 2.5  1026, by t-test). Further, such
measurements in LCLs from three asymptomatic carriers
from these same families showed that PRPF31 expression
levels ranged from 0.53 to 0.67 a.u. As expected, these
values were lower than, but within the same range as those
resulting from LCLs from the normal population, while still
being higher than those detected in LCLs from affected
patients (P ¼ 0.01, by t-test).
PRPF31 expression in the CEPH cell lines was measured to
calculate heritability of this molecular phenotype. Specifically,
we found heritability to be 0.45 (P ¼ 5.09  1025), as
assessed by the SOLAR (Sequential Oligogenic Linkage
Analysis Routines) software (34), indicating that variable
PRPF31 expression is a highly heritable trait in the general
population. We also estimated the likelihood of detecting sig-
nificant eQTL (expression quantitative trait locus) to be 70%,
given the size of our CEPH panel and such a high heritability.
eQTL linkage analysis
We performed multipoint genome-wide linkage analyses using
the MERLIN REGRESS and MERLIN VC algorithms (34) on
all 200 CEPH samples to identify chromosomal regions poten-
tially involved in the regulation of PRPF31 expression. LOD
scores from MERLIN REGRESS and MERLIN VC were
highly correlated (r ¼ 0.98, by the Pearson’s test), indicating
that the results obtained were indeed robust. Since the
MERLIN REGRESS algorithm has been shown to be more
powerful in large sibships (3) than MERLIN VC (35), the
latter method was used only as an internal control. A significant
linkage peak (LOD score¼ 3.83, P ¼ 1 1025, Fig. 3, Table 1)
was found on chromosome 14 at 69.36 cM from pter. To assess
the robustness of this result, we randomly separated 12 times the
Figure 2. Quantification of PRPF31 mRNA expression in lymphoblastoid cell lines (LCLs). Sorted expression levels of PRPF31 mRNA in LCLs from 200
control individuals (CEPH), 3 asymptomatic (AS) and 7 affected (AFF) patients with PRPF31 mutations are shown, as measured by real-time PCR.
PRPF31 mRNA expression is normalized to a median expressor, arbitrarily set to have a value of 1.0. Error bars refer to the standard error of the mean.
Figure 3. Results of genome-wide quantitative multipoint linkage analysis. Result plot obtained from the regress-based method implemented in the MERLIN
software (53). The continuous horizontal line indicates the threshold for significant LOD scores and the dotted line is the threshold for ‘suggestive linkage’, as
defined by Lander and Kruglyak (56). A significant peak with a LOD score of 3.83 (P ¼ 1  1025) was detected at 69.36 cM from the pter of chromosome 14.
Four other LOD scores suggestive of linkage were observed on chromosome 5, 14 and 19 (containing two peaks). The location of PRPF31 on chromosome 19 is
indicated.
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15 families analyzed into a ‘test’ (8 families) and a ‘validation’
group (7 families). For each of these sets, eQTL analyses were
re-assessed by the same methods, with markers belonging to
chromosome 14. We found that, for all 12 simulations, the
peak originally detected in the 15 families was always present
in each of the ‘test’ sets and in the corresponding ‘validation’
sets. These results indicate that all families analyzed likely con-
tributed to the eQTL signal on chromosome 14, and that we can
confidently exclude the possibility of a false-positive result in the
original set of 200 cell lines.
Four other suggestive linkage sites, indicated in Table 1,
were also revealed on chromosomes 5, 14 and 19 (containing
two peaks). Noteworthy, the RP11 locus is also located on
chromosome 19, however, it is very distant from both these
loci. The LOD-1 95% confidence interval (CI) (36) of the sig-
nificant linkage peak in the 14q22.1–23.1 region identified a
8.2-Mb interval containing 97 genes, as deduced from the
genome database at NCBI (National Center for Biotechnology
Information), build 36.2 (www.ncbi.nlm.nih.gov). Of these, at
least 50 were previously assessed to be expressed in LCLs by
whole-genome microarray expression analysis of 210 LCLs
(37) and may have therefore contributed to this eQTL.
Among these 50 genes, there were some transcription factors
or genes involved in transcription regulation such as CGR19,
WDHD1 and TXNDC1 that can potentially direct or modulate
PRPF31 mRNA expression. Furthermore, the region identified
has been shown to have a major role in retinal physiology as it
contains three genes: OTX2, BMP4 and SIX6 that are strongly
involved in retinal development and maintenance (38–40).
Seventeen out of these 50 expressed genes correspond to pro-
teins with no known established function.
Considering this newly identified regulator of PRPF31
expression localized on chromosome 14, designated from
this point onwards as the ‘RP11-distant regulator’, we
propose a classical model for the function of this eQTL
(Fig. 4A and B). In this model, the modifier gene, which is
variably expressed because of a common polymorphism,
would encode a diffusible element (e.g. a transcription
factor) modulating the expression of PRPF31. In this scenario,
irrespective of the total expression, the two alleles of PRPF31
would always be expressed in a 50:50 ratio.
PRPF31mRNA allelic expression in the general population
The reduced penetrance of hereditary elliptocytosis (30) and
erythropoietic protoporphyria (31) is modulated in each case
by the variable expression of the wild-type allele, which is
in turn directly influenced by the presence of a polymorphism
in cis with it, i.e. in trans with respect to the mutation.
Based on these two well-documented dominant diseases
and by adapting these paradigms to our current model of
an RP11-distant regulator, we investigated whether the
expression of the PRPF31 wild-type allele could be enhanced
Figure 4. Models for regulation of PRPF31 expression. Diagrammatic rep-
resentation of various models by which the RP11-distant regulator eQTL
identified in this study and RP11-associated isoalleles may affect the
expression of PRPF31. Open rectangles are the graphical representations of
segments of interest of chromosomes 14 and 19. Red and green rectangles
on chromosome 14 correspond to polymorphic alleles of the RP11-distant
regulator. Black circles represent proteins or other diffusible modulators pro-
duced by this eQTL. Hatched rectangles indicate the PRPF31 locus. Blue and
red arrows symbolize allelic and total PRPF31 mRNA amounts, respectively,
their thickness being proportional to the rate of expression. (A and B) Sche-
matic representation of an individual who does not carry any RP11-associated
isoallele. In a heterozygote individual for a polymorphic allele in the
RP11-distant regulator, one eQTL allele produces more modifier than the
other, resulting eventually in increased PRPF31 total mRNA production.
Regardless of the genotype at the RP11-distant regulator locus and of the
total PRPF31 mRNA production, each PRPF31 allele contribute equally to
gene expression. (C) Model of an individual carrying an RP11-associated iso-
allele (green ‘A’). Hypothesizing that this isoallele acts in cis, inducing
PRPF31 expression (orange arrow), an overexpression of the corresponding
PRPF31 allele should be observed, compared to the allele in trans. (D) Alter-
natively, RP11-associated isoalleles producing a diffusible element (green
squares) could act in cis and in trans, increasing with equal strength the
amount of PRPF31 pre-mRNA and mRNA derived from both alleles.
Table 1. Summary of the genome-wide multipoint linkage analysis performed
using the MERLIN REGRESS algorithm
Chromosome Marker Position (cM) LOD score P-value
5 rs2043833 167.14 1.99 1.2  1023
14 rs1889383 69.36 3.83 1  1025
14 rs1959287 159.1 2.58 3  1024
19 rs1862471 30.68 1.95 1.4  1023
19 rs1122713 40.69 2.23 7  1024
Only significant (3.3) and suggestive (1.9) LOD scores are reported.
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by RP11-associated isoalleles acting as cis regulatory elements
(Fig. 4C).
To test this model, we quantified in our set of CEPH cell
lines the individual expression of both PRPF31 alleles, when-
ever these could be specifically identifiable by molecular tags.
Specifically, we selected all SNPs within the PRPF31 tran-
script sequence, from the Ensembl database (www.ensembl.
org) and from our own sequencing data, that create or
abolish a restriction site and are present in at least one pedi-
gree among all tested CEPH families. Overall, we identified
2 SNPs that matched these criteria and 65 CEPH individuals
from 11 families were found to carry one of these 2 SNPs.
No cell line was found to carry both. One (rs1058572 in
exon 7) is an A/G transition creating an EarI restriction site
and the second is a C/T transition in exon 14 (provisionally
reported in the Ensembl database as ENSSNP6991476) creat-
ing anMseI restriction site. For all cell lines displaying hetero-
zygosity at one of these sites, we found that the allelic ratio of
PRPF31 expression was approximately 50:50, regardless of
the total expression (Fig. 5). This indicates that the mRNAs
derived from both PRPF31 alleles are present in equal
amounts, disfavoring the presence of any modifiers acting
exclusively in cis with respect to a given allele in the tested
set of CEPH cell lines.
Effects of RP11-associated isoalleles on PRPF31 expression
The absence of cis-acting PRPF31 expression modulators in
the CEPH cell lines analyzed does not exclude per se that
some RP11-associated isoalleles are actually present in such
a set, if they act in cis as well as in trans (Fig. 4D). Indeed,
previous studies in families segregating such isoalleles did
hypothesize but never demonstrated that, similar to FECH
and SPTA1, these modifiers also act exclusively in cis
(12,28). To gain insights into the mechanisms of action of
RP11-associated isoalleles, we performed total and allelic
quantification in LCLs from definite carriers of such isoalleles,
with or without PRPF31 mutations, as ascertained by previous
investigations on RP11 families, and having various clinical
classifications (Table 2). We analyzed LCLs from four asymp-
tomatic carriers and five affected patients from three RP11
families for which individual alleles could be distinguished
because of sequence variations. Given that mature mRNA
from carriers of heterozygous PRPF31 mutations is not
suitable for allelic expression quantification, because only
mRNA derived from wild-type alleles exists at the steady
state (29), we quantified the allelic expression of PRPF31 at
the nuclear pre-mRNA level. The same was repeated on the
one individual, referenced as AG261, who is a non-carrier of
PRPF31 mutations but is an obligate heterozygous carrier of
an RP11-associated isoallele. This individual is the spouse
of a carrier of a PRPF31 mutation from family #AD5 and
has five children, of whom one affected and two asymptomatic
patients underwent clinical examination (8,41).
Results clearly showed that LCLs from all carriers of
RP11-associated isoalleles (asymptomatics and AG261) had
more PRPF31 pre-mRNA than those from non-carriers, i.e.
affected patients (P ¼ 8.38  1024, by t-test, Fig. 6), and
that this increase pertained equally to both wild-type and
mutant alleles. This indicates that, similar to RP11-distant
regulators, RP11-associated isoalleles enhance PRPF31
transcription by acting on both alleles. Because of this
phenomenon, an ancillary conclusion is therefore that some
of the high LCLs expressors from the CEPH panel (Fig. 2)
could possibly represent unascertained carriers of RP11-
associated isoalleles that, unlike all expressors measured in
the past, do not carry any PRPF31 mutations. This same situ-
ation is shared by cell line AG261, which would actually be
the fifth highest expressor if its total mRNA expression is
compared with all 200 CEPH cell lines analyzed initially
(not shown).
DISCUSSION
Dominant mutations in PRPF31 (or RP11) leading to RP are
subject to reduced penetrance (6–12,14,18–20,22–25). This
phenomenon, which is not due to the presence of regional
CNVs, has in turn been shown to be determined by the
expression levels of PRPF31 mRNA derived from the wild-
type allele (21,26,28). Although photoreceptors and lympho-
blasts are very different cell types, a number of studies have
demonstrated a strong link between penetrance of PRPF31
mutations and elevated PRPF31 expression in LCLs derived
from asymptomatic carriers of mutations with respect to
affected patients (21,28,29). To investigate genetic determi-
nants of PRPF31 expression we used an unbiased approach,
independent from the presence of PRPF31 mutations. Specifi-
cally, we took advantage of the fact that CEPH cell lines are
widely genotyped and have often been used as a powerful
system to detect genetic linkage for quantitative traits
Figure 5. PRPF31 mRNA allelic expression in CEPH cell lines. Data (black
dots) are represented as the ratio of one allele over the total PRPF31 mRNA
expression, and were generated by RFLP analyses of PRPF31 coding SNPs
present in 65 heterozygous CEPH cell lines. Total expression of PRPF31
mRNA was measured by real-time PCR. Dotted ovals delimit expected
values in the hypothesized model of an exclusive cis-acting regulation of
PRPF31 expression by the RP11-associated isoalleles. Under this assumption,
one allele should be more expressed than the other in LCLs from heterozygous
individuals (with the genotypes Aa). ‘A’ and ‘a’ stand for the presence or
absence of the RP11-associated isoallele, respectively, as defined in Fig. 1.
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(42,43), including eQTLs (37), and analyzed LCLs from
200 control individuals from 15 families by real-time PCR.
Our data show that the steady-state expression of PRPF31
mRNA is variable and heterogeneous within the general popu-
lation (Fig. 2). As expected, LCLs from seven affected
patients, carrying different mutations and used as positive
controls, had lower amounts of PRPF31 mRNA than LCLs
sampled from the general, unaffected population, since the
mRNA derived from the mutant PRPF31 allele was inacti-
vated by nonsense-mediated mRNA decay (29). As a further
Table 2. Lymphoblastoid cell lines from families showing incomplete penetrance of PRPF31 mutations
Family ID Individual ID PRPF31 mutation Clinical status Reference
1562 13189 Not characterized Affected Berson et al. (6,7)b, McGee et al. (12), Rivolta et al. (21).
12943 Asymptomatic
13191 Asymptomatic
2474 14284 c.877_910del Affected Berson et al. (7)b, McGee et al. (12), Rivolta et al. (21).
13991 Asymptomatic
AD5 AG293 c.1115_1125del Affected Moore et al. (8)b, Evans et al. (41)b, Al Maghteh et al. (10),





aObligate heterozygous carrier of an RP11-associated isoalleles.
bClinical description.
Figure 6. PRPF31 pre-mRNA total and allelic quantification in LCLs from carriers of RP11-associated isoalleles. AD5, 2474 and 1562 indicate the family codes
for individuals AG261, AG293, AG305, AG307, AG316, AG340, 14284, 13991, 12943 and 13189. AFF, AS and UN refer to affected and asymptomatic patients,
or the unaffected control AG261, respectively. Diamond symbols indicate total PRPF31 pre-mRNA expression (right ordinates). Bars represent allelic quanti-
fications, as percents of total expression, of pre-mRNA from either the PRPF31 wild-type (white) or mutant (black) allele (left ordinates). Error bars are standard
errors of the mean. In all families, LCLs from carriers of an RP11-associated isoallele (asymptomatics and AG261) express more PRPF31 pre-mRNA than those
from affected patients, but all cell lines express the same ratio of allelic pre-mRNA, regardless of the presence of mutations and of the clinical classification of the
donors. Total pre-mRNA expression is normalized relatively to the LCLs from affected individuals AG293, 14284 and 13189 for families #AD5, #2474 and
#1562, respectively.
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control, LCLs from three asymptomatic patients were shown
to have amount of PRPF31 mRNA within the range of the
unaffected population and higher than those from affected
patients (Fig. 2), as predicted (21,28). By significantly extend-
ing the size of the samples representing the unaffected
population, we therefore confirm and reinforce what was pre-
viously demonstrated in families with PRPF31 mutations, i.e.
that low expression of PRPF31 mRNA is the cause of
the disease and that incomplete penetrance is mediated by
modifiers modulating PRPF31 mRNA expression.
We next demonstrated that PRPF31 mRNA expression was
highly heritable among the examined families (H2r ¼ 0.45,
P ¼ 5.09  1025), indicating that genetic elements are pre-
dominantly involved in modulating the amounts of PRPF31
transcripts. We performed a whole-genome non-parametric
linkage analysis to map eQTLs (Fig. 3), and identified a
genomic region on chromosome 14q22.1–23.1 (LOD score¼
3.83, P ¼ 1  1025, Table 1) that was significantly linked to
variation in PRPF31 mRNA expression levels. The 95% CI
encompasses an 8.2-Mb DNA sequence and contains 97
genes. Fifty-eight of these genes have been analyzed in
CEPH trios expression studies: 50 were indeed expressed in
LCLs (37), 17 of which are not functionally characterized.
Among these 50 genes, some encode for transcription factors
or proteins that are involved in regulation of transcription
such as: CGR19, WDHD1 and TXNDC1. Moreover, this
region plays a major role in retinal physiology as it contains
three genes: OTX2, BMP4, and SIX6 that are strongly involved
in human retinal development and maintenance (38–40).
Interestingly, the gene closest to the SNP yielding the
maximum LOD score is OTX2 (Drosophila orthodenticle
homolog 2), which has a major role in the embryonic for-
mation of the human eye. Specifically, it controls the develop-
ment of photoreceptors and determines their fate (44) and also
regulates the expression of rhodopsin (45), a function that
could be in turn a causal determinant of RP. However,
OTX2 is not expressed in LCLs (37) and it is therefore unlikely
to have contributed to the observed eQTL. In short, no obvious
candidate genes could be identified at this stage but our data
provide an excellent starting point for future investigations.
It is worth noticing, however, that the large majority of
genes present in this region (57 of the 97) produce proteins
or hypothetical proteins for which no precise function is
currently known.
We considered a classical model for the regulation of
PRPF31 expression by the chromosome 14 eQTL, also referred
to as the RP11-distant regulator. Within this model, we hypoth-
esized that this modifier could be variably expressed, depending
on polymorphic variants in its sequence, and in turn modulate
PRPF31 expression. As a consequence, we expected both
PRPF31 alleles to be expressed in a 50:50 ratio (Fig. 4A and
B), independently from the total PRPF31 expression. This
was indeed the case, as allelic measurements of PRPF31
expression in all 65 CEPH LCLs that were suitable for such
investigations revealed that, although they expressed very vari-
able amounts of total PRPF31 mRNA (from 0.6 to 2.4 a.u.),
they each expressed both alleles with equal strength (Fig. 5).
Previous studies located another modifier onto chromosome
19, within or near the PRPF31 gene. Indeed, reduced
penetrance of PRPF31 mutations was previously demon-
strated by sib pair analysis in families with asymptomatic
and affected patients to be significantly linked to alleles
present within the RP11 locus itself or associated to a
closely linked locus (RP11-associated isoalleles) (12,13).
Specifically, in a meta-analytical study of 26 sibling pairs
from four different families with RP11-linked RP, McGee
et al. found that 10 sib pairs with the same PRPF31 mutation
and the same clinical status (either affected or asymptomatic)
shared the same wild-type allele inherited from the parent who
did not carry the mutation (12). Conversely, 13 of 16 sib pairs
with divergent phenotypes, despite being carriers of the same
mutation, inherited different haplotypes from the healthy non-
carrier parent. Since penetrance of PRPF31 mutations is deter-
mined by PRPF31 mRNA expression, by measuring PRPF31
mRNA levels in CEPH cell lines we expected to find a signal
on chromosome 19, near the RP11 locus. Yet, no significant
LOD score was observed in the region where these RP11-associ-
ated isoalleles were mapped. Suggestive linkage peaks were,
however, found on chromosome 19, but as far as 50–60 cM
away from the PRPF31 sequence (Fig. 3). Failure to detect
this modifier in our linkage analysis could be due to sampling
and size effects. Specifically, we arbitrarily selected healthy
CEPH families whereas other studies have selectively targeted
RP11 families that contained asymptomatic patients, and this
may have introduced an ascertainment bias. There are no
reliable estimates on the frequency of these RP11-associated iso-
alleles in the general population. Hence, it is impossible to esti-
mate the likelihood of identifying them in the studied CEPH
families. However, it is an intriguing possibility that the
seven highest CEPH expressors (Fig. 2), showing very distin-
ctive expression profiles, may indeed be carriers of RP11-
associated isoalleles.
We next wanted to specifically investigate RP11-associated
isoalleles, and we focused our research on LCLs derived from
definite carriers of such isoalleles, ascertained from previously
described RP11 families. Similar to PRPF31-linked RP, the
penetrance of the hereditary elliptocytosis (30) and the ery-
thropoietic protoporphyria (31) is modulated by the expression
of the allele in trans to the mutant allele. In the latter two
diseases, the amount of wild-type mRNA is regulated by a
cis-acting polymorphism. Based on this model, we investi-
gated whether the RP11-associated isoalleles would also act
as in cis elements. This model, depicted in Fig. 4C, could
explain the asymptomatic status of carriers of RP11-associated
isoalleles since wild-type PRPF31 alleles would be overex-
pressed when the isoalleles are present. Under the assumption
of a cis-mediated effect, the two alleles of PRFP31 would not
be expressed in a 50:50 ratio. To test this, and circumvent
problems associated with nonsense-mediated mRNA decay,
we performed total and allele-specific pre-mRNA quantifi-
cations in cell lines from five affected and from four asympto-
matic patients. Our results showed that PRPF31 transcripts
derived from both alleles were present approximately in a
50:50 ratio, regardless of the total PRPF31 expression,
indeed higher in asymptomatics, and of the patients’ clinical
status (Fig. 6). The same held true for PRPF31 pre-mRNA
from LCLs from an individual (AG261) who does not carry
any PRPF31 mutation and is an obligate heterozygous
carrier of an RP11-associated isoallele (Fig. 6). In addition,
total mRNA from LCLs from this individual was elevated
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with respect to other normal controls, making AG261 the fifth
expressor if compared with the original CEPH set. Our data
thus suggest that RP11-associated isoalleles do modulate
PRPF31 expression by acting on both alleles, with equal
strength (Fig. 4D), unlike the classical models of hereditary
elliptocytosis and erythropoietic protoporphyria (30,31). This
isoalleles-based regulation would most likely imply a diffusi-
ble compound, a protein or a regulatory RNA, exercising its
activity at a very early stage of RNA synthesis, since its
effects are detectable at the PRPF31 pre-mRNA level. Specifi-
cally, it is possible that this diffusible modulator could
enhance PRPF31 transcription or, conversely, be a less effi-
cient expression downregulator. This latter scenario would
indeed be in perfect agreement with a model of putative
PRPF31 downregulation by sense-antisense pairing between
two neighboring transcripts, TFPT and PRPF31, that has
been suggested by Anandalakshmi et al. (46). Furthermore,
such modulation is independent from the presence of
PRPF31 mutations, as demonstrated by the analysis of
AG261. However, overexpression of mutant PRPF31 mRNA
in both patients and asymptomatic carriers has virtually no
effect, as the large majority of PRPF31 mutations are
degraded by nonsense-mediated mRNA decay (29). The net
overall functional result of the presence of RP11-associated
isoalleles in carriers of mutations is therefore the increase of
mature PRPF31 transcripts from the wild-ype allele only, con-
ferring to asymptomatic patients resistance to the disease
(21,28).
In light of all our results, we propose that PRPF31
expression is managed according to a co-regulatory model,
based on the effect of at least two modulators whose mode
of action and relative impact on expression regulation
remain to be determined. Within this model, the product of
a genetic element located in the 14q21–23 region is proposed
to regulate the transcription of both PRPF31 alleles, an event
that can probably be defined as the most common situation, at
least according to our arbitrary sampling of the general popu-
lation. Furthermore, independently from the presence of
modulators from chromosome 14, RP11-associated isoalleles
could also play a role in increasing the amounts of
pre-mRNA from both PRPF31 copies during the transcription
process (Fig. 4D). The study by McGee et al. (12) showed that
there were 3 out of 26 sibling pairs who had different pheno-
types and inherited the same in trans haplotypes, indicating
that other modifiers, such as the RP11-distant regulator,
could indeed be determinants of penetrance, independently
from RP11-associated isoalleles. This notion is also supported
by observations that carriers of the same PRPF31 mutation
who share the same clinical classification may display
variations in severity of the disease (8,11,23–25).
Penetrance is frequently determined by either the influence
of alleles in trans and in close proximity with respect to the
mutation [hereditary elliptocytosis (30), erythropoietic proto-
porphyria (31) and breast and ovarian cancer (47)] or by one
or several modifier genes at loci unlinked to the gene
causing the disease [autosomal recessive deafness (48) and
cystic fibrosis (49)]. PRPF31-linked RP appears to be a dis-
order for which incomplete penetrance of dominant mutations
could be tightly influenced by a combinatorial effect of very
specific regulators, nearby as well as distant.
MATERIALS AND METHODS
Cell lines and cell culture
Epstein-Barr virus transformed LCLs from 200 members of 15
CEPH families (50), namely families #102, #884, #1328,
#1331, #1332, #1333, #1334, #1340, #1341, #1345, #1346,
#1347, #1362, #1408 and #13292 were purchased from the
Coriell Cell repository (http://ccr.coriell.org). Cells were
grown at a density of 0.4–1  106 cells/ml in RPMI 1640
with Glutamax I medium supplemented with 15% of foetal
bovine serum and 1% penicillin/streptomycin mix. LCLs
from three families segregating various PRPF31 mutations
are reported in Table 2. LCLs derived from affected patients
AG293, AG305, AG307, 13189 and 14284 and asymptomatic
patients 12943, 13191 and 13991 from three families each
with different mutations in PRPF31were obtained and cultured
as described previously (21,29). Asymptomatic individual
13991 (III-7) is the father of 14284 (IV-8), who is affected
[family #2474, Fig. 1 in McGee et al. (12)]. In family #1562,
affected individual 13189 (IV-30) is the daughter of 13191
(III-12), who is asymptomatic as is her sister, 12943 (III-15)
[Fig. 1 in McGee et al. (12)]. LCLs representative of asympto-
matic carriers used for the experiment depicted in Fig. 2 were
from individuals 12943, 13191, and 13991. Asymptomatic
patient cell lines (AG316, AG340) and control cell line
AG261 from a family (#AD5) segregating the c.1115_
1125del mutation [Fig. 1 in Moore et al. (8), Evans et al. (41)
and Vithana et al. (28)] were purchased from the European Col-
lection of Cell Cultures. AG293 is the affected child of AG316,
who is an asymptomatic carrier of the c.1115_1125del mutation.
Another branch of the family is represented by AG340
(asymptomatic) and AG261 (non-carrier) (28). Classification of
individuals in specific clinical categories (affected patients,
asymptomatic carriers of mutations and controls) was the same
as the one originally made by the authors who first examined
these individuals and reported their diagnostic assessment
(6–8). These clinical evaluations were made at a time when
the causative gene responsible for the disease was still
unknown and were therefore not biased by the presence or
absence of specific PRPF31 genotypes.
RNA extraction and retrotranscription
Total and nuclear RNA from 10 million cultured cells was
extracted and retrotranscribed as previously described (29).
Briefly, all mRNA analyses were performed on cDNA syn-
thesized from total RNA using an oligo-dT, whereas products
of retrotranscription of nuclear RNA, treated with RNAse-free
DNase I (Roche), were retrotranscribed with random hexamers
and used for pre-mRNA analyses. To confirm that genomic
DNA was absent from cDNA preparations, control reactions
lacking the reverse transcriptase enzyme (2RT) were always
performed. These preparations were run in parallel to and used
as negative controls for every PCR and real-time PCR reaction.
PRPF31 mRNA quantification by real-time PCR
Quality of total RNA was assessed through 260/280 nm and
260/240 nm absorbance ratios and by calculating the 28S/18S
ratio using the HDA-GT12 Multi-Channel Genetic Analyzer
Human Molecular Genetics, 2008, Vol. 17, No. 20 3161
(eGene, Inc.). Only RNA with a 28S/18S ratio above 1.4 was
retained for further investigations. Expression of PRPF31
mRNA (Genbank accession no. NM_015629.2) was measured
by quantitative real-time PCR using an ABI Prism 7900 HT
Real-time PCR system (Applied Biosystems). Reactions
were performed in a final volume of 20 ml containing
TaqMan Universal PCR Master Mix (Applied Biosystems)
and 80 ng of retrotranscribed mRNA. Primers and probe
were designed to specifically amplify cDNA derived from
PRPF31 mRNA (Supplementary Table) and a pre-developed
TaqMan Endogenous Control (VIC/MGB probe) (Applied
Biosystems) was used to amplify GAPDH cDNA derived
from mRNA (Genbank accession no. NM_002046.3). Reac-
tions were set-up in 384-well plates by a Freedom Evo 200
robot (Tecan). Each plate contained the two premixes, able
each to amplify either PRPF31 or GAPDH cDNA, and one
copy of each sample. Furthermore, replicated twice on each
plate, two serial dilutions of samples composed by a mix of
cDNA from CEPH cell lines were added to measure the effi-
ciency of the two PCR set-ups. This checked the accuracy of
pipetting (i.e. same Ct values for the two replicates of stan-
dards in a same plate) and the reproductibility and robustness
of each PCR set-up (i.e. same Ct values for standards and
same PCR efficiencies on different plates). Overall, PRPF31
and GAPDH expression from each sample was measured
five times on five different plates for a total of 2000 inde-
pendent real-time PCR amplifications. Biological reproducibil-
ity was tested by randomly selecting 82 cell lines from the
analyzed CEPH individuals and by growing each one of
them again as two independent cultures. RNA for each of
these 164 samples was re-extracted and re-assessed for both
PRPF31 and GAPDH expression by following the same pro-
cedures. The same replications were applied to all LCLs
derived from families segregating PRPF31 mutations.
All plates were analyzed using the same threshold to ensure
uniformity of the analyses. Ct values for all samples were
confirmed to be within the Ct range of the serial dilutions.
Since efficiencies of the two PCR were approximately equal,
PRPF31 mRNA expression was normalized with respect to
GAPDH, using the DDCt method, for each sample and was
expressed as a relative quantity, with respect to the median
PRPF31 mRNA expressor. Outliers were defined using the
Chauvenet’s criterion and removed.
Genotypes, heritability and linkage analyses
The CEPH cell panel of SNP markers was obtained from the
CEPH genotype database V10.0 (http://www.cephb.fr/cephdb/).
A genetic map consisting of 2713 SNP markers genotyped for
the 15 CEPH families and with known NCBI position
(dbSNP build 124) was established. The SNP centiMorgan
map positions were interpolated from the Rutgers Linkage-
Physical Map (http://compgen.rutgers.edu/maps/) (51). The
marker set was screened with PedCheck (52). No Mendelian
inconsistencies or unlikely genotypes were detected.
To estimate the part of the phenotypic variance that is due to
total additive genetic variance, heritability was calculated
using the polygenic function of the SOLAR software (34).
To identify eQTLs involved in the regulation of PRPF31
expression, genome-wide multipoint linkage analyses were
performed using two different methods implemented within
the MERLIN software (53): a variance components algorithm
(MERLIN-VC) and a regression-based algorithm (MERLIN-
REGRESS) (35).
The distribution of PRPF31 expression was right-skewed
(skewness ¼ 1.2) and, as computed by the SOLAR software,
had a residual kurtosis of 1.9, which denotes a significant
shift from the normal distribution (data not shown). Such a
departure from the Gaussian curve has been shown to cause
inflated type I errors during linkage analyses (54,55). There-
fore, we applied a log10 transformation to the raw phenotypes,
and obtained a set of values showing a final residual kurtosis
of 20.2 and a skewness of 20.2, more typical of a normal
distribution, as confirmed by a Kolmogorov–Smirnov test
(data not shown). Therefore, the log10 transformed values of
PRPF31 expressions were used as a phenotype for linkage
analyses.
LOD score significance thresholds were set as sugges-
ted by Lander and Kruglyak (56), i.e. a LOD score  3.3
(P ¼ 4.9  1025) was defined to correspond to a genome-wide
‘significant linkage’ and a LOD score  1.9 (P ¼ 1.7 1023)
to indicate ‘suggestive linkage’.
mRNA and pre-mRNA allelic quantification
by SNP analysis
Regions containing SNPs that create restriction sites in the
mRNA and genomic DNA were amplified using specific
primers to generate PCR products of equal sizes on the
genomic DNA and cDNA (Supplementary Table). Hetero-
zygous carriers were identified by analyzing their genomic
DNA using restriction fragment length polymorphism
(RFLP). PCR were performed in a total volume of 25 ml, con-
taining 1 Expand High Fidelity PCR System buffer with
MgCl2, 100 mM dNTP mix, 200 nM of each primer and 1 U
of Expand High Fidelity PCR System (Roche). PCR cycling
conditions were 948C for 2 min followed by 40 cycles of
15 s at 948C, 30 s at 608C and 1 min at 688C and by a final
elongation step of 10 min at 688C. RFLP analysis was done
in a total volume of 16.25 ml by incubating 10 ml of PCR pro-
ducts with 1 appropriate NEB Buffer, 1 BSA when
required, and 10 U of restriction enzyme at 378C for 2 h.
To quantify pre-mRNA or mRNA allelic expression, for
each SNP analyzed, it was first necessary to create quantifi-
cation standards. Two different genomic DNA templates
from CEPH cell lines that were homozygous for either the
major or minor SNP alleles were mixed to obtain quantifi-
cation standards in the following ratios: 70/30, 65/35, 60/40,
55/45, 50/50, 45/55, 40/60, 35/65 and 30/70, at concentrations
that could generate as much PCR products as cDNA (to avoid
differences in signal strength). cDNA from samples, quantifi-
cation standards and controls (homozygous and heterozygous
genomic DNA, cDNA derived from homozygotes for either
SNP alleles) were amplified on the same plate. PCR products
were then digested by the relevant restriction enzyme. RFLP
analysis was performed by capillary electrophoresis, i.e. by
running digested PCR products on the HDA-GT12 Multi-
Channel Genetic Analyzer (eGene, Inc.) and quantification
was achieved using the Biocalculator software (eGene, Inc.).
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PCR products from homozygous variations of genomic DNA
and cDNA were used as controls for the digestion.
The logarithm of the values of the quantification standards
was plotted against ratios measured by the Biocalculator soft-
ware. Linear regression analysis showed that the R2 was at
least 0.99. Ratios calculated by the software were reported
on this regression curve to determine the allelic expression
of each sample. Quantification of heterozygous DNA was
confirmed to be in a 50:50 ratio. Pre-mRNA allelic quanti-
fications were performed by RFLP for family #1562 (6)
(using SNP rs1058572) and for the control individual
AG261 (using the intronic SNP rs11673377).
Pre-mRNA allelic quantification by real-time PCR
Oligonucleotides specific for either the mutant or the non-
mutant cDNA derived from pre-mRNA from patients carrying
PRPF31 mutations were used for allele-specific real-time PCR
(Supplementary Table). PCR products were subcloned into
pcDNA3.1/V5-His TOPO TA vectors (Invitrogen). The result-
ing plasmids were sequenced using BigDye Cycle Terminator
v1.1 Cycle Sequencing Kit (Applied Biosystems) and used to
generate quantification standards, by combining non-mutant
and mutant sequences in the following ratios: 90/10, 80/20,
70/30, 60/40, 50/50, 40/60, 30/70, 20/80, 10/90. Reactions
were performed using an ABI Prism 7500 Sequence Detector
(Applied Biosystems) in a final volume of 20 ml containing
Power Sybr Green Master Mix (Applied Biosystems) and
600 ng of retrotranscribed nuclear RNA. PCR efficiencies
were determined by amplifying standard dilutions of patient
cDNA and derived plasmids. Efficiencies were confirmed
to be identical for cDNA and plasmids for the same
allele (mutant or non-mutant). To quantify the expression
of mutant and non-mutant alleles, cDNA from LCLs from
patients, the heterozygous genomic DNA carrying the same
PRPF31 mutation, and plasmid quantification standards were
run in triplicate on the same plate for each family sharing
the same mutation.
Expression analysis used the relative standard curve
method, with wild-type pre-mRNA as reference and mutant
pre-mRNA as target. Standards and genomic DNA from
LCLs from patients were also quantified to validate the accu-
racy of the allele-specific real-time PCR. Pre-mRNA allelic
quantifications were performed by allele-specific real-time
PCR for carriers of PRPF31 mutations in families #AD5 (8)
and #2474 (7).
Pre-mRNA quantification by real-time PCR
To quantify the expression of PRPF31 pre-mRNA from nuclear
RNA, PCRprimerswere designed to specifically amplify cDNA
derived only from pre-mRNA (Supplementary Table). Reac-
tionswere performed using anABI Prism 7500SequenceDetec-
tor in a final volume of 20 ml containing either the Power Sybr
Green Master Mix or the TaqMan Universal PCR Master Mix
(Applied Biosystems) and 600 ng of retrotranscribed
nuclear RNA. The pre-developed TaqMan Endogenous
Control (VIC/MGB probe) that amplifies GAPDH cDNA
derived from mRNA was used to normalize PRPF31
pre-mRNA expression during quantification. Standard curves
were generated, for both PRPF31 pre-mRNA and GAPDH
mRNA, using a 5-fold serial dilution over a 375-fold range of
a pool of cDNA samples to be analyzed. Similar efficiencies
for the two PCR reactions allowed the relative quantification
of the amount of PRPF31 pre-mRNA in cell lines derived
from patients by the DDCt method.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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